CLUSTER filed Aug 10, 2026 at 16:38 ET
CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in open-market shares within two days of United Therapeutics' Q2 2026 earnings, which showed a 2% revenue miss and 4% decline in total Tyvaso sales. While the dollar amount is trivial relative to the $22.7B market cap (0.004%), the timing, immediately after a mixed earnings report, and the CEO's exercise of 9,500 options for cashless net-share settlement suggest the sales are primarily liquidity-driven rather than a bearish signal. The cluster is neutral: the CEO's sales follow a typical post-exercise pattern, and the EVP's sale is modest. No material directional read-through for the stock.